User login
Readily available clinical measures can be used to reliably predict long-term outcome in patients with chronic HCV infections and well-compensated advanced liver disease, Dr. Adriaan J van der Meer, of Erasmus University Medical Center, Rotterdam, The Netherlands, and his colleagues report.
The researchers devised risk scores for mortality and for cirrhosis-related complications from a cohort of 405 patients, 100 of whom died during about 8 years of follow up. They then applied the model to 296 patients, 59 of whom died during 6 years of follow up. Independent predictive factors included age, male sex, platelet count, and aspartate aminotransferase/alanine aminotransferase ratio, the researcher said in an article published in the January issue of Gut ( Gut 2015;64:322-331).
Click here to read the article in Gut: http://gut.bmj.com/content/64/2/322.abstract
Readily available clinical measures can be used to reliably predict long-term outcome in patients with chronic HCV infections and well-compensated advanced liver disease, Dr. Adriaan J van der Meer, of Erasmus University Medical Center, Rotterdam, The Netherlands, and his colleagues report.
The researchers devised risk scores for mortality and for cirrhosis-related complications from a cohort of 405 patients, 100 of whom died during about 8 years of follow up. They then applied the model to 296 patients, 59 of whom died during 6 years of follow up. Independent predictive factors included age, male sex, platelet count, and aspartate aminotransferase/alanine aminotransferase ratio, the researcher said in an article published in the January issue of Gut ( Gut 2015;64:322-331).
Click here to read the article in Gut: http://gut.bmj.com/content/64/2/322.abstract
Readily available clinical measures can be used to reliably predict long-term outcome in patients with chronic HCV infections and well-compensated advanced liver disease, Dr. Adriaan J van der Meer, of Erasmus University Medical Center, Rotterdam, The Netherlands, and his colleagues report.
The researchers devised risk scores for mortality and for cirrhosis-related complications from a cohort of 405 patients, 100 of whom died during about 8 years of follow up. They then applied the model to 296 patients, 59 of whom died during 6 years of follow up. Independent predictive factors included age, male sex, platelet count, and aspartate aminotransferase/alanine aminotransferase ratio, the researcher said in an article published in the January issue of Gut ( Gut 2015;64:322-331).
Click here to read the article in Gut: http://gut.bmj.com/content/64/2/322.abstract